A new trading day began on Tuesday, with Athira Pharma Inc (NASDAQ: ATHA) stock price up 8.40% from the previous day of trading, before settling in for the closing price of $0.43. ATHA’s price has ranged from $0.22 to $3.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -73.94% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 72.22%. With a float of $33.48 million, this company’s outstanding shares have now reached $39.04 million.
In an organization with 26 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Athira Pharma Inc (ATHA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Athira Pharma Inc is 14.24%, while institutional ownership is 45.17%. The most recent insider transaction that took place on Jul 01 ’25, was worth 2,502. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 8,526 shares at a rate of $0.29, taking the stock ownership to the 168,901 shares. Before that another transaction happened on Jul 01 ’25, when Company’s President and CEO sold 25,123 for $0.29, making the entire transaction worth $7,374. This insider now owns 325,802 shares in total.
Athira Pharma Inc (ATHA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 56.32% during the next five years compared to -73.94% drop over the previous five years of trading.
Athira Pharma Inc (NASDAQ: ATHA) Trading Performance Indicators
Here are Athira Pharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.07, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Athira Pharma Inc (ATHA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.27 million. That was inferior than the volume of 0.38 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 67.05%.
During the past 100 days, Athira Pharma Inc’s (ATHA) raw stochastic average was set at 93.33%, which indicates a significant increase from 90.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0463 in the past 14 days, which was higher than the 0.0324 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3243, while its 200-day Moving Average is $0.4278. However, in the short run, Athira Pharma Inc’s stock first resistance to watch stands at $0.4844. Second resistance stands at $0.5016. The third major resistance level sits at $0.5183. If the price goes on to break the first support level at $0.4505, it is likely to go to the next support level at $0.4338. Assuming the price breaks the second support level, the third support level stands at $0.4166.
Athira Pharma Inc (NASDAQ: ATHA) Key Stats
With a market capitalization of 18.24 million, the company has a total of 39,042K Shares Outstanding. Currently, annual sales are 0 K while annual income is -96,940 K. The company’s previous quarter sales were 0 K while its latest quarter income was -9,140 K.
